We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Qiagen Collaborates with Institut Curie to Develop High-Throughput RNAi Tools
News

Qiagen Collaborates with Institut Curie to Develop High-Throughput RNAi Tools

Qiagen Collaborates with Institut Curie to Develop High-Throughput RNAi Tools
News

Qiagen Collaborates with Institut Curie to Develop High-Throughput RNAi Tools

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Qiagen Collaborates with Institut Curie to Develop High-Throughput RNAi Tools"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Qiagen and Institut Curie have announced a collaboration to develop tools for high-throughput RNAi screening as part of the Institut Curie BioPhenics project.

This project, led by Drs Jacques Camonis and Franck Perez, aims to use RNAi technology in conjunction with advanced systematic phenotypic analysis to accelerate cancer drug discovery.

“As one of the largest cancer research centers in Europe, part of the ongoing research at Institut Curie is dedicated to the understanding of how cells become cancerous,” said Jacques Camonis, head of the BioPhenics project in the Translational Department at Institut Curie.

“The goal of the 'BioPhenics' project is to apply cell biology and microscopic imaging to cancer research for a deeper understanding, improved target validation and, ultimately, more efficient cancer drug discovery.”

“Qiagen is pleased to be able to contribute to this ambitious and exciting research,” said Jie Kang, V.P. of R & D at Qiagen.

“The combination of Qiagen advanced siRNA design and extremely efficient HiPerFect delivery reagent should contribute greatly to the overall goals of the project.”

Advertisement